The aesthetic year opened in Paris, where manufacturers used IMCAS 2026 to preview what is coming to the syringe — including TrenibotE, a fast-on, short-off type-E toxin unlike anything currently on the U.S. market. Here is what stood out, and what is still under review.
The IMCAS World Congress 2026, held January 29–31 in Paris, was the aesthetic industry's first major scientific gathering of the year. Its headline injectable news was new data across neurotoxins and fillers — most notably TrenibotE, a first-in-class type-E botulinum toxin designed for fast onset and short duration — alongside new long-term data for established products.
The International Master Course on Aging Science (IMCAS) World Congress is one of aesthetic medicine's largest annual events, drawing dermatologists, plastic surgeons, and roughly 400 exhibiting companies to Paris. The 2026 edition ran January 29–31 and functioned, as it does each year, as an early barometer for the treatments and technologies that will shape the rest of the year.
On the injectable side, Allergan Aesthetics (an AbbVie company) announced ahead of the meeting that it would present nine e-posters spanning its on-market and emerging facial portfolio. The most closely watched item was TrenibotulinumtoxinE ("TrenibotE"), described as a first-in-class botulinum neurotoxin of serotype E — distinct from the type-A toxins (such as Botox, Dysport, Xeomin, and Jeuveau) that dominate the market. Type-E toxin is engineered to act quickly and wear off sooner, a profile the company has positioned for patients who want to "test-drive" a neuromodulator or prefer results measured in weeks rather than months. TrenibotE was under FDA review for frown lines heading into 2026.
The company also highlighted Phase 4 (post-approval) data for onabotulinumtoxinA in the upper face, pointing to the benefits of long-term, repeated use and patient satisfaction with natural-looking outcomes — part of a broader industry theme of "subtle" rather than "frozen" results.
Allergan was not alone. Galderma presented clinical data at IMCAS 2026 as well, including a controlled investigation of a hyaluronic acid filler for temple hollowing — an area of growing interest as providers address volume loss across the whole face rather than treating wrinkles in isolation.
For consumers, congress data is the earliest signal of what may reach a provider's treatment menu. New product categories — short-acting toxins, next-generation fillers, and biostimulatory options — expand choice, but they also mean more nuance at the point of consultation. Importantly, congress data and FDA approval are not the same thing: a product presented in Paris may still be months or years from U.S. availability, and review status can change.